Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Oxford-Harrington Rare Disease Centre is redoubling efforts to develop a therapeutics programme for Friedreich’s Ataxia.

Researchers working in a laboratory with medical equipment

Friedreich’s Ataxia (FA) is a debilitating, life-shortening, degenerative neuromuscular rare disorder, with onset during childhood. Despite high levels of existing medical research around FA, significant further progress is needed to advance new treatments.

The Oxford-Harrington Rare Disease Centre (OHC) has the expertise and capability to contribute to the major effort underway aimed at developing effective treatments for FA in the near future. The OHC combines the University of Oxford and the Harrington Discovery Institute's world-leading strengths in research and therapeutics development. The OHC was formed to set the science and innovation agenda, driving cutting-edge rare disease breakthroughs to address the unmet need in rare disease across the globe and to deliver major clinical impact for patients. Friedreich’s Ataxia is a compelling initial focus area given this goal.

The OHC has adopted FA as a priority area within its neurological disorders theme. Ultimately, the OHC hopes to participate meaningfully in developing a therapy to treat or potentially cure FA through coordinated research efforts, leveraging the full strengths of the University of Oxford and the Harrington Discovery Institute, and externally with leading institutions across the world to focus efforts on therapeutic interventions with immediate potential.

OHC will be building on the long history of important contributions to the FA field by Oxford researchers. As a first step in this new journey, with the support of EndFA, a philanthropic partner focused on FA, the OHC has recruited a new Research Facilitator in Friedreich’s Ataxia. Dr Geoffrey Denwood joined the OHC at the University of Oxford site in April 2021, and will dedicate his time and expertise into coordinating the activities of the OHC in FA. Dr Denwood will evaluate the current status of FA translational research and therapeutics development locally and globally, then work to fund and implement an OHC programme harnessing the best expertise and most promising therapeutic opportunities.

For more information please contact info@oxfordharrington.org.

Similar stories

New Studentship honours Enzo Cerundolo

A new Studentship has been announced in memory of the late MRC HIU Director and MRC WIMM Group Leader.

Young lives under pressure as global crises hits mental health and well-being – report

The well-being and mental health of young people in low - and middle - income countries have been dramatically affected by the series of crises hitting the world. As the international community continues to struggle with the impact of COVID-19, conflict and climate change, the latest report from the Young Lives project shows a long-running upward trend in young people’s well-being has been sharply reversed alongside widespread anxiety and depression. Young people are less confident about their futures for the first time in the 20-year study.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

New tool aims to make bowel cancer treatments more effective

The Leedham Lab in Nuffield Department of Medicine (NDM) has been awarded over £2M from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Doug Higgs awarded the 2023 Genetics Society Medal

The award recognises Radcliffe Department of Medicine's Professor Higgs major contribution to our understanding of how mammalian genes are switched on and off, and using haematopoiesis as a model to understand how genes function.